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ABSTRACT
A human skin explant model has been used to predict the clinical outcome and to study the immunopathology of
human graft-versus-host disease (GVHD). Whether the model gives the same predictive effect for GVHD in
different hematopoietic stem cell transplantation (HSCT) settings has not been assessed. It is also unknown
whether the skin explant result reflects the known biological risk factors for clinical GVHD. In this study, the skin
explant model was used to detect graft-versus-host reactions (GVHR) in vitro for 225 eligible patient/donor pairs.
The predicted skin GVHR grade was correlated with the outcome of clinical GVHD, as well as HLA matching
status, sex mismatches, and patient age. In sibling HSCT under either myeloablative or reduced-intensity condi-
tioning, a significant correlation was observed between the predicted skin GVHR and clinical GVHD (P< .001 and
P .033, respectively). InHSCTusing unrelated donors, the involvement of T-cell depletion led to a sharp increase
in false-positive GVHR results, and no correlation was observed between the predicted skin GVHR and clinical
GVHD. The skin GVHR grade correlated significantly with the HLAmatching status (HLA-matched sibling pairs,
HLA-matched unrelated pairs, and HLA-unmatched unrelated pairs). Furthermore, HLA-matched sibling pairs
with a female-to-male sex mismatch had a significantly higher overall skin GVHR grade and a higher ratio of high-
versus low-grade skin GVHR than the sibling pairs with all other sex combinations. Patient age was not reflected
in the skin explant result. In conclusion, the predictive value of the skin explant model for aGVHD varies depending
on the clinical transplant protocols, such as the type of GVHD prophylaxis used. Nevertheless, the skin explant
model remains a unique in vitro system that provides an in situ histopathologic readout for studying alloreactivity
and humanGVHD. Themodel has also the potential to aid the development of novel prophylaxis and treatment for
GVHD.
© 2006 American Society for Blood and Marrow Transplantation
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Hematopoietic stem cell transplantation (HSCT)
s increasingly used to treat a variety of malignant and
onmalignant diseases. Despite improvements in the
bility to type and match HLA antigens between do- t
52or and recipient, graft-versus-host disease (GVHD)
emains a major obstacle to successful allogeneic
SCT, contributing substantially to morbidity and
ransplant-related mortality. Because GVHD is fre-
uently refractory to treatment, great effort and at-
ention have been focused on the early identiﬁcation
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Skin Explant Model of Human GVHD
Bf high-risk patients [1-6]. The accurate prediction of
he occurrence and severity of GVHD could help
irect the application of treatment strategies before
he appearance of clinical manifestations so that the
omplication can be prevented by alternative or addi-
ional prophylactic immunosuppression. An in vitro
uman skin explant model was originally described by
ogelsang et al. [7] to predict the occurrence of acute
VHD (aGVHD) in bone marrow transplant recipi-
nts. The model has since been established and used
uccessfully in our center for predicting aGVHD in
onventional myeloablative HSCT from HLA-
atched siblings, with an 80% overall correct predic-
ion rate [8,9]. The skin explant model has also fre-
uently been used to study the mechanisms and
mmunopathology of human GVHD. Previous studies
ave demonstrated the roles of CD4/CD8 T-cell
ubsets and minor histocompatibility antigen–speciﬁc
ytotoxic T lymphocyte clones, as well as the levels of
ytokines, including interferon , tumor necrosis fac-
or , and interleukin 10, in the severity of graft-
ersus-host reactions (GVHR) in skin [10-13]. A novel
se of a human skin explant model has also been
ighlighted in a recent investigation for the immuno-
iological consequences of conditioning regimens on
esident host cells [14]. Over the last decade, the trend
n allogeneic HSCT has shown an increased use of
educed-intensity conditioning regimens and HLA-
atched unrelated donors (MUD). These changes in
linical transplantation practice have inevitably inﬂu-
nced the immunobiological process of GVHD.
hether the skin explant model retains its predictive
ower for aGVHD in HSCT with reduced-intensity
onditionings or MUDs has not yet been assessed. It
s also unknown whether the biological risk factors for
VHD can be reﬂected by the skin explant results.
In this study, we evaluated the use of the skin
xplant model for predicting aGVHD in HLA-
atched sibling HSCT with either conventional my-
loablative or reduced-intensity preparative regimens
nd in HSCT with MUDs. This was the ﬁrst attempt
o investigate and compare the predictive value of the
kin explant model for aGVHD in different allogeneic
SCT settings. To further test the validity of the skin
xplant as a model of human GVHD, the skin explant
esult was correlated, for the ﬁrst time, with the bio-
ogical risk factors of clinical GVHD, including the
LA matching status, female-to-male sex mismatch,
nd older patient age.
ATERIALS AND METHODS
Ethics Committee approval was obtained for all
spects of this study. Written informed consent was
btained from all patients and donors for blood and
kin biopsy samples. Ethics approval and informed -
B&MTonsent were also obtained for using blood donations
rom healthy volunteer blood donors.
A total of 225 eligible patient/donor pairs were
ollected from 4 HSCT centers as a European collab-
rative project (Newcastle, UK; Regensburg, Ger-
any; Vienna, Austria; and Prague, Czech Republic).
he patients were divided into 3 cohorts. Cohort 1 (n
126) included patients who had HSCT from HLA-
atched sibling donors under conventional myeloab-
ative conditioning regimens. Cohort 2 (n  44) in-
luded patients who received a transplant from HLA-
atched sibling donors under reduced-intensity
onditioning regimens. Cohort 3 (n  55) included
atients who received a transplant from MUDs. The
yeloablative conditioning regimen used for the
LA-matched sibling transplants was mainly frac-
ionated total body irradiation (TBI) combined with
ither melphalan (Mel) or cyclophosphamide (Cy) (n
85). A proportion of patients were conditioned with
usulfan (Bu)  Cy or Bu  Mel without TBI (n 
1). The reduced-intensity conditioning regimens
sed for the HLA-matched sibling transplantations
onsisted of ﬂudarabine (Flu)  Mel (n  15), Flu 
el  Campath (Schering Health Care Ltd, West
ussex, UK) (n  18), Flu  Mel  carmustine (n 
), or Flu  cytosine arabinoside  Mel (n  7).
atients in the MUD transplant cohort received either
yeloablative conditioning regimens (n  39; TBI 
y, TBI  Mel, Bu  Cy, Bu  Mel, Flu  Cy, or
BI  Cy  Flu) or reduced-intensity conditioning
n  16; Flu  Mel). The vast majority of MUD
ransplant patients (48/55) had T-cell depletion by in
ivo application of either Campath or antithymocyte
lobulin. GVHD prophylaxis for all cohorts was cyclo-
porin A (CsA) alone, CsA  methotrexate (MTX), or
sAmycophenolate mofetil. The clinical characteris-
ics of all patients are shown in Table 1. Acute GVHD
as graded by using the Glucksberg criteria [15]. Pa-
ients were considered assessable for aGVHD if they
urvived for more than 30 days after a myeloablative
ransplantation. Because of the nature of delayed onset of
GVHD in nonmyeloablative HSCT [16], patients were
onsidered assessable for aGVHD if they survived more
han 100 days after transplantation. Patients were also
onsidered assessable if they died before 30 or 100 days
ith signiﬁcant GVHD for myeloablative and nonmy-
loablative transplantation, respectively.
LA Typing
The HLA typing was performed by using medi-
m- to high-resolution molecular typing with poly-
erase chain reaction sequence-speciﬁc primers for
LA-A, -B, -Cw, -DRB1*, -DQB1*, and DPB1*. For
he sibling transplant cohort, all patient/donor pairs
ere fully matched for HLA-A, -B, -Cw, -DRB1*, and
DQB1*. For the unrelated donor transplant cohort,
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190% of patient/donor pairs were fully matched at
LA-A, -B, -Cw, -DRB1*, and -DQB1*. Five out of
5 patient/donor pairs had 1 mismatch at the HLA-B
r -Cw allele. HLA-DPB1* was typed for 17 MUD
ransplant patient/donor pairs. Four out of 17 had 1 or
-DP mismatches.
ell Preparation and Culture Conditions
Peripheral blood was obtained from patients and
onors 4 weeks before transplantation. Peripheral
lood mononuclear cells (PBMCs) were separated by
ensity gradient centrifugation over Lymphoprep
Nycomed Pharma AS, Oslo, Norway). RPMI 1640
edium (GIBCO, Paisley, UK) supplemented with
enicillin, streptomycin, l-glutamine (GIBCO, Pais-
ey, UK), and 10% heat-inactivated human AB serum
as used for mixed lymphocyte reactions (MLRs).
he same medium supplemented with 20% heat-in-
ctivated patient autologous serum was used for skin
oculture. All the cultures were incubated at 37°C in a
umidiﬁed 5% carbon dioxide in 95% air incubator.
kin Explant Model
The skin explant model has been described in
etail previously [17,18]. The model consists of 3
ain steps, including a primary MLR to activate do-
or-allospeciﬁc T cells, a coculture of patient skin
ith activated donor T cells to induce graft-versus-
able 1. Characteristics of Patients in Different Transplantation
ohorts
Characteristic
Cohort 1
(n  126)
Cohort 2
(n  44)
Cohort 3
(n  55)
edian age, y (range) 35 (17-60) 44 (21-59) 34 (18-56)
ex (male/female) 77/49 28/16 33/22
tem cells (BM/PBMCs) 106/20 8/36 38/17
iagnosis
AML  ALL 78 14 30
CML 34 4 14
NHL  HD  MM 11 23 9
Others 3 3 2
ampath or ATG
Yes 0 20 48
No 126 24 7
VHD prophylaxis
CsA alone 61 20 18
CsA  MTX 65 19 30
CsA  MMF 0 5 7
ohort 1 indicates HLA-matched sibling HSCT with myeloabla-
tive conditioning; cohort 2, HLA-matched sibling HSCT with
reduced-intensity conditioning; cohort 3, MUD transplantation
with myeloablative or reduced-intensity conditioning; AML,
acute myelogenous leukemia; ALL, acute lymphoblastic leuke-
mia; CML, chronic myelogenous leukemia; NHL, non-
Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple my-
eloma; ATG, antithymocyte globulin; CsA, cyclosporin A;
MTX, methotrexate; MMF, mycophenolate mofetil; BM, bone
marrow; PBMC, peripheral blood mononuclear cells.ost (GVH)–type tissue damage, and an in situ his- a
54opathologic evaluation of the severity of skin tissue
amage. Brieﬂy, the MLR was set up in the GVH
irection by using patient PBMCs as stimulator cells
20 Gy of irradiation) and an equal number of donor
BMCs as responder cells. At day 7 of MLR, standard
-mm punch skin biopsy samples were obtained from
atients. The skin biopsy samples were trimmed of
xcess dermis, dissected into small sections of equal
ize, and cocultured with MLR-primed donor re-
ponder cells. The skin sections cultured with medium
lone were used as background controls. After 3 days
f coculture, skin sections were ﬁxed in 10% buffered
ormalin and stained with hematoxylin and eosin. The
istopathologic evaluation of the skin sections was
erformed blindly by 2 observers and conﬁrmed by an
ndependent histopathologist. On the basis of the se-
erity of histopathologic changes, skin GVHR was
eﬁned as grades I to IV (Figure 1) according to the
erner grading system [19]. All background controls
isplayed a skin GVHR of grade I or less. A skin
VHR of grade II or above was considered as a high
rade or as positive. In the case of the HLA-un-
atched situation, the MLR was set up by using PB-
Cs from patients who underwent autologous HSCT
r plastic surgery as stimulators and PBMCs from an
nrelated healthy blood donor as responders. The
LR-primed cells were then cocultured with skin
ections taken from the corresponding stimulator.
he statistical signiﬁcance for the association between
redicted skin GVHR and clinical aGVHD was ana-
yzed by using the 2 test. The differences in overall
kin GVHR grade between groups with various HLA
atching statuses, different sex combinations, and
arious age ranges were analyzed by using the Mann-
hitney test. Multivariate analysis was undertaken by
sing binomial logistic regression with a forward step-
ise model and an inclusion cutoff of 0.15 (SPSS
oftware version 11; SPSS Inc., Chicago, IL). The
odel was built by using skin GVHR grade (grade 0-I
ersus grades II-IV), patient age (40 versus 40
ears), sex disparity (female to male versus others),
ytomegalovirus (CMV) status (negative for both pa-
ient and donor versus others), and GVHD prophy-
axis (CsA alone versus CsA  MTX).
ESULTS
orrelation of Skin GVHR and Clinical aGVHD in
LA-Matched Sibling Transplantations with
onventional Myeloablative Conditioning
A total of 126 patient/donor pairs were included in
his cohort. The results were initially analyzed as a
hole regardless of the type of GVHD prophylaxis. A
igniﬁcant association was observed between the pre-
icted skin GVHR grade and the outcome of clinical
GVHD, with a total correct prediction rate of 64%
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BP .001; Table 2). The negative predictive value was
tronger than the positive predictive value (72% ver-
us 58%, respectively). Further analysis of subgroups
f patients with different types of GVHD prophylaxis
evealed that variation in GVHD prophylaxis could
igniﬁcantly affect the GVHD prediction value. The
redictive power of the skin explant model was signif-
cantly improved in the cohort that received CsA only
s GVHD prophylaxis, in which the overall correct
rediction rate was 79% (P  .0001; Table 2), corre-
igure 1. Histopathologic changes for different grades of skin GVH
ells. B, Grade II skin GVHR showing diffuse vacuolization of epide
pidermis and dermis caused by conﬂuent vacuolar damage to basal
f the epidermis and dermis.
able 2. Correlation of Predicted Skin GVHR and Clinical aGVHD
n HLA-Matched Sibling HSCT with Conventional Myeloablative
onditioning
Skin GVHR Acute GVHD Grade
0–I II–IV
ll patients (n  126; P < .001)
Grade 0–I 34 13
Grade II–IV 33 46
atients with CsA along as GVHD prophylaxis (n  61; P <
.0001)
Grade 0–I 24 5
Grade II–IV 8 24
atients with CsA  MTX as GVHD prophylaxis (n  65; P 
.864)
Grade 0–I 10 8c
Grade II–IV 25 22
B&MTponding to a positive predictive value of 75% and a
egative predictive value of 83%. No correlation,
owever, was then found in the remaining cohort,
hich had received CsA  MTX prophylaxis (P 
864; Table 2). This means that the predictive effect of
he skin explant model observed here is mainly due to
he cohort of patients who received CsA alone as
VHD prophylaxis. To determine whether the skin
xplant result was able to predict aGVHD indepen-
ently, the multivariate analysis was undertaken for
he sibling myeloablative transplant cohort, in which
he largest number of patient/donor pairs was con-
ained. In a model built by using skin GVHR grade,
atient age, sex disparity, CMV status, and GVHD
rophylaxis, only the skin GVHR result was signiﬁ-
antly predictive of aGVHD (grade II and above; odds
atio, 4.77; P  .001). When the skin GVHR data
ere excluded from the model, sex disparity showed a
rend, although its predictive effect did not reach
tatistical signiﬁcance (odds ratio, 1.88; P  .10).
orrelation of Skin GVHR and Clinical aGVHD in
LA-Matched Sibling Transplantations with
educed-Intensity Conditioning and in MUD
ransplantations
The skin GVHR results and clinical GVHD out-
Grade I skin GVHR showing very mild vacuolization of epidermal
ells. C, Grade III skin GVHR showing cleft formation between the
ocytes. D, Grade IV skin GVHR showing the complete separationR. A,
rmal c
keratinomes for the sibling transplantation cohort with re-
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1uced-intensity conditioning are shown in Table 3.
he results demonstrated a signiﬁcant correlation (P
.033) between the predicted skin GVHR and the
ccurrence of clinically signiﬁcant aGVHD (grade II
nd above). The overall correct prediction rate was
6% (29/44), with a positive predictive value of 64%
16/25) and a negative predictive value of 68% (13/
9). In the MUD transplant cohort, 42 of 55 patients
ere predicted to have high-grade skin GVHR (grade
I or higher). Only a third (14/42) of them developed
GVHD of grade II or above after transplantation.
linically signiﬁcant aGVHD also occurred in 7 of 13
atients with predicted low-grade skin GVHR. The
verall correct prediction rate was as low as 36%
20/55), with a positive predictive value of 33% (14/
2) and a negative predictive value of 46% (6/13).
tatistical analysis conﬁrmed that there was no signif-
able 3. Correlation of Predicted Skin GVHR and Clinical aGVHD
n Sibling Transplantations with Reduced-Intensity Conditioning and in
UD Transplantations
Skin GVHR
Acute GVHD
Grade
0–I II–IV
ibling transplant patients with
reduced-intensity conditioning
(n  44; P  .033)
Grade 0–I 13 6
Grade II–IV 9 16
UD transplant patients with
myeloablative or reduced-intensity
conditioning (n  55; P  .183)
Grade 0–I 6 7
Grade II–IV 28 14
igure 2. Association of skin GVHR grade with HLA matching sta
LA-matched related, HLA-matched unrelated, and HLA-unmatched un
56cant association between the predicted skin GVHR
rade and the outcome of clinical aGVHD for this
articular cohort of patients (P  .183; Table 3).
aking the conditioning regimens and GVHD pro-
hylaxis into consideration, the analysis was also per-
ormed for separate subgroups of patients deﬁned ei-
her by the type of conditioning as myeloablative (n 
9) versus reduced intensity (n  16) or by the type of
VHD prophylaxis as CsA alone (n  18) versus CsA
MTX or CsA  mycophenolate mofetil (n  37).
o correlation between the predicted skin GVHR
rades and clinical aGVHD was observed in any of
hese subgroups (data not shown).
orrelation of Skin GVHR and Biological Risk
actors for aGVHD
To explore whether the skin explant result could
eﬂect the HLA matching status, the skin GVHR
rade was analyzed for 3 groups of allogeneic stimu-
ator/responder pairs representing 3 different degrees
f HLA matching status. The HLA-matched sibling
roup mainly demonstrated grade I and II skin
VHR, whereas grade III and IV skin GVHR dom-
nated the HLA-unmatched unrelated group (P 
0001; Mann-Whitney test). The overall skin GVHR
rade of the HLA-matched unrelated group was sig-
iﬁcantly higher than that of the HLA-matched sib-
ing group (P  .017) but was signiﬁcantly lower than
hat of the HLA-unmatched unrelated group (P 
004; Figure 2a). The ratios of high-grade (II or
igher) versus low-grade (less than II) skin GVHR
ere 1.6 (104:66), 3.2 (42:13), and 19.5 (39:2) for the
LA-matched related, HLA-matched unrelated, and
LA-unmatched unrelated groups, respectively. The
combinations, and patient age. In Figure 2A, a, b, and c representtus, sex
related allopairs, respectively.
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Skin Explant Model of Human GVHD
Bifferences between any of the 2 groups were statisti-
ally signiﬁcant (P  .04, P  .012, and P  .0001,
espectively; 2 test).
Another signiﬁcant clinical risk factor for GVHD
s transplantation from a female donor to a male re-
ipient [20,21]. The skin GVHR results from HLA-
atched siblings were then analyzed in 2 subgroups
ith different sex combinations. One group consisted
f the sex combination of female as responder and
ale as stimulator (female to male; n  52). Another
roup consisted of sex combinations of either both
ale or both female as stimulator and responder (male
o male or female to female) or male as responder and
emale as stimulator (male to female; n  118). The
nalysis revealed that the overall skin GVHR grade in
he female-to-male sex mismatch group was signiﬁ-
antly higher compared with the results for the com-
arison group with all other forms of sex combina-
ions (P  .031; Mann-Whitney test; Figure 2b). The
atio of high-grade (II or higher) versus low-grade
less than II) skin GVHR was 3.3 (40:12) in the fe-
ale-to-male mismatch group and 1.1 (63:55) in the
omparison group. The difference between the 2
roups was statistically signiﬁcant (P  .004; 2 test).
urthermore, compared between HLA-matched sib-
ing pairs with female-to-male sex mismatch and
LA-matched unrelated pairs, there were no signiﬁ-
ant differences in terms of either overall skin GVHR
rade or the ratio of high- versus low-grade skin
VHR (3.3 versus 3.2, respectively).
Patient age was an important issue in HSCT until
he introduction of the reduced-intensity conditioning
egimens established recently [22,23]. An older pa-
ient age has been reported to contribute to increased
everity of GVHD and to be a poor prognostic factor
or survival after HSCT [21,24]. The skin GVHR
esults from HLA-matched siblings were therefore
lso analyzed in 3 groups deﬁned by the age ranges of
5 to 30, 31 to 45, and 46 to 60 years. The age factor
as, however, not reﬂected in the skin explant result.
here were no signiﬁcant differences in the overall
kin GVHR grade between any of the age groups
Figure 2c). The ratios of high-grade (II or higher)
ersus low-grade (less than II) skin GVHR were vir-
ually the same for 3 groups (1.53, 1.55, and 1.58,
espectively).
ISCUSSION
A human skin explant model has been used to
redict the clinical outcome and to study the immu-
opathology of human GVHD. Whether the model
ives the same predictive effect for GVHD in differ-
nt HSCT settings has not been assessed. It is also
nknown whether the skin explant result reﬂects the
elevant biological risk factors for clinical GVHD. In r
B&MThis study, the predictive value of the human skin
xplant model for aGVHD was evaluated in 3 cohorts
f patients who received different forms of allogeneic
SCT in terms of conditioning regimens, GVHD
rophylaxis, and donor sources. The results revealed
hat the skin explant model predicts aGVHD to a
arying degree depending on the clinical procedure of
he transplantation.
For HLA-matched sibling HSCT with conven-
ional myeloablative conditioning, a previous report of
6 patients demonstrated that the predicted skin
VHR grades correlated with aGVHD occurrence in
0% of cases [8,9]. A further observation from a small
n 19) mixed cohort of adults and children indicated
reduced predictive effect of the skin explant model
or clinical aGVHD when the patients were given
ncreased GVHD prophylaxis of CsAMTX [25]. In
his study, we have conﬁrmed, in a larger European
ulticenter cohort (n  126) containing only adult
atients, that the skin explant results could be highly
redictive of aGVHD in HLA-matched sibling
SCT with conventional myeloablative conditioning
egimens. The accuracy of the prediction was, how-
ver, GVHD prophylaxis dependent, and the signiﬁ-
ance of the correlation between the predicted skin
VHR grade and the occurrence of clinical aGVHD
ay only in a cohort of patients who received CsA
lone as GVHD prophylaxis. In multivariate analysis,
he skin explant results retained independent predic-
ive power over sex disparity, patient age, CMV status,
nd GVHD prophylaxis. This may suggest that the
kin GVHR grade is a more precise predictive factor
nd probably reﬂects other unknown complex biolog-
cal factors, such as the inﬂuence of cutaneous minor
istocompatibility antigens. It was unexpected that
one of the known clinical risk factors included in the
nalysis demonstrated a signiﬁcant predictive effect
or aGVHD except a trend in female-to-male sex
isparity. This is very likely due to the inadequate
ample size. Clinical risk factors are usually reﬂected
n large registry studies and can be modulated by
herapeutic interventions.
A signiﬁcant correlation between predicted skin
VHR and clinical aGVHD after sibling HSCT with
educed-intensity conditioning suggested that the skin
xplant model has the potential to be used in this
ohort to identify patients who might be at a higher
isk of developing aGVHD so that alternative or ad-
itional GVHD prophylaxis can be considered. Mean-
hile, the effect of different GVHD prophylaxis and
n vivo T-cell depletion in this particular cohort is
orthy of further investigation when a larger cohort
f patients is available. The observation from the
UD transplant cohort demonstrated a total lack of
orrelation between the predicted skin GVHR grade
nd clinical GVHD. Clinically, the number of allo-
eactive T cells present in the donor graft is undoubt-
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1dly the most signiﬁcant risk factor for the develop-
ent of aGVHD after transplantation. The vast
ajority of MUD transplant patients received in vivo
onor T-cell depletion, and this could have resulted in
signiﬁcant reduction in the occurrence of clinical
GVHD [26,27]. It is likely that T-cell depletion, by
igniﬁcantly reducing the incidence of clinical
VHD, will decrease the predictive power of the skin
xplant model as a result of a sharp increase in the
alse-positive skin GVHR results. The removal of
onor T cells could therefore be the most important
actor inﬂuencing the predictive value of the skin
xplant model for aGVHD, regardless of the type of
VHD prophylaxis.
Although the value of the skin explant model for
VHD prediction can be inﬂuenced and limited by
he clinical transplantation procedures, the model re-
ains a valuable tool for studying the immunopathol-
gy of human GVHD. Previous studies using the
odel have demonstrated the roles of CD4/CD8
-cell subsets and minor histocompatibility antigen–
peciﬁc cytotoxic T-lymphocyte clones, as well as the
evels of cytokines, including interferon , tumor ne-
rosis factor , and interleukin 10, in the severity of
VH reactions [10-13]. The immunobiological con-
equences of conditioning regimens on resident host
ells have also been demonstrated by using a skin
xplant model system [14]. This study shows, for the
rst time, a signiﬁcant correlation between the skin
VHR result and known biological risk factors for
GVHD. A total of 61% of HLA-matched sibling
airs and 76% of HLA-matched unrelated pairs gave
ise to positive skin GVHR (grade II and above), thus
ndicating a signiﬁcant role of the alloresponses in-
uced by the disparity of undetected major and/or
inor histocompatibility antigens. The correlation
etween high-grade skin GVHR and female-to-male
ex mismatch was in line with our recently published
bservations showing that direct cellular inﬁltration of
-Y minor histocompatibility antigen–speciﬁc cyto-
oxic T cells caused severe GVH reactions in male
kin [11]. Indeed, the data presented here have re-
ealed for the ﬁrst time in vitro that the ratio of high-
ersus low-grade skin GVHR for HLA-matched sib-
ing pairs with female-to-male sex mismatch was as
igh as that for HLA-matched unrelated pairs. This
as highlighted the importance of alloreactivity in-
uced by the disparity of minor histocompatibility
ntigens in HSCT and provided novel in vitro bio-
ogical evidence for clinically observed increased
VHD incidence and severity in female-to-male
SCT [20,21]. Furthermore, the direct correlation
etween the skin GVHR grade and the frequency of
lloreactive cytotoxic T-lymphocyte precursors [28]
irrors the clinical fact that the dose of alloreactive T
ells present in the donor graft is one of the most
igniﬁcant risk factors for the development of
58GVHD after transplantation. One of the signiﬁcant
linical risk factors for aGVHD, namely, older patient
ge, has not been reﬂected in the skin explant result.
his is not surprising. The mechanisms related to the
igher risk of GVHD and poor outcome after trans-
lantation in older patients are apparently not entirely
ased on alloreactive T-cell responses. It could be
nﬂuenced by complex overall effects, including an
dvanced stage of disease, modiﬁcation of the immune
ystem associated with aging, general ﬁtness, altered
harmacokinetics, and the capacity of multiorgan
unction to cope with the transplantation procedure
24,29,30].
In conclusion, the predictive value of the skin
xplant model for aGVHD varies depending on the
linical procedure of the transplantation. The model
an be highly predictive of aGVHD, but only in se-
ected cohorts of patients. Increased GVHD prophy-
axis with CsA  MTX and the use of donor T-cell
epletion could diminish the predictive power of the
kin explant model. Because of the changes in the
linical transplantation procedures over recent years,
t was necessary to reevaluate the predictive power of
he model for GVHD in different transplantation set-
ings. Currently the clinical risk factors and pathology
f aGVHD have been well described, but the cellular
echanisms are more difﬁcult to study without an
ntact tissue environment. The skin explant model is
n informative in vitro system that most closely mim-
cs the in vivo mechanisms and pathology of human
GVHD. The model gives a functional indication for
he immune responses induced by the disparities in
ajor and/or minor histocompatibility antigens and
rovides a unique in situ histopathologic readout for
tudying human GVHD. The model has also the
otential to aid the development of novel prophylaxis
nd treatment for GVHD.
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